Senior Scientist

Career Opportunities with Summit Therapeutics Sub, Inc.

A great place to work.

Careers At Summit Therapeutics Sub, Inc.

Current job opportunities are posted here as they become available.

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, andour commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology.

Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

HARMONi:
Phase 3 clinical study which was intended to evaluateivonescimabcombined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locallyadvancedor metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

HARMONi-3:
Phase 3 clinical study which is intended to evaluateivonescimabcombined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

HARMONi-7:
Phase 3 clinical study which is intended to evaluateivonescimabmonotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

HARMONi-GI3:
Phase 3 clinical study intended to evaluateivonescimabin combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimabis an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and hasadditionaloffices in California, New Jersey, the UK, and Ireland.

Overview of Role:

The Senior Scientist will take primary ownership of laboratory activities. It is a highly hands-on position to drive the research of the mechanism of action (MOA) of ivonescimab and related bispecific antibodies, and to play an integral role in the discovery and development of pipeline molecules.

Role and Responsibility:

• MOA Research
  :
  Design and execute in vitro and in vivo studies, work with CROs and academic labs to elucidate the mechanism at the molecular, cellular and tumor-immune system levels. Translate the findings into a deeper understanding of therapeutic efficacy and resistance biology in different cancer indications that can guide indication expansion, rational drug combinations, and biomarker development.
• Pipeline Development
  :
  Design and execute experiments to create, characterize and advance the development of candidate molecules.
• Contribution to cross-functional governance: Produce in-depth analyses as well as executive summaries to inform internal stakeholders. Serve as the subject matter expert in cross-functional teams to facilitate decision-making. Author conference abstracts and presentations, submit manuscripts to peer-reviewed journals to share findings with the scientific and medical communities.
• Contribution to competitive intelligence
  collection: Evaluate emerging technologies, literature, and competitive landscapes to inform innovation and pipeline development.
• All other duties as assigned, including the maintenance of Summit research facilities.

Experience, Education and Specialized Knowledge and

Skills:

• PhD with 3+ years or MS with 5+ years industry experience in Immunology, Cancer Biology, Molecular/Cellular Biology, or related fields.
• Demonstrated expertise and a strong publication record in immuno-oncology and/or angiogenesis biology fields.
• Strong technical skills in the design, execution and data analysis using wild type or genetically engineered syngeneic tumor model in mice, as well as xenogeneic/PDX tumor model in mice; using organoid systems and primary human leukocytes.
• Technical proficiency in design, execution…